These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12687554)

  • 1. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
    Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
    Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
    Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
    Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
    Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
    J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.
    Saag KG; Agnusdei D; Hans D; Kohlmeier LA; Krohn KD; Leib ES; MacLaughlin EJ; Alam J; Simonelli C; Taylor KA; Marcus R
    Arthritis Rheumatol; 2016 Sep; 68(9):2122-8. PubMed ID: 27111239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z; Ellakwa H; Desouky B
    Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
    Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
    Devogelaer JP; Broll H; Correa-Rotter R; Cumming DC; De Deuxchaisnes CN; Geusens P; Hosking D; Jaeger P; Kaufman JM; Leite M; Leon J; Liberman U; Menkes CJ; Meunier PJ; Reid I; Rodriguez J; Romanowicz A; Seeman E; Vermeulen A; Hirsch LJ; Lombardi A; Plezia K; Santora AC; Yates AJ; Yuan W
    Bone; 1996 Feb; 18(2):141-50. PubMed ID: 8833208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
    Frost ML; Siddique M; Blake GM; Moore AE; Marsden PK; Schleyer PJ; Eastell R; Fogelman I
    Osteoporos Int; 2012 Aug; 23(8):2107-16. PubMed ID: 21983795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.